A prospective, double-blind, pilot, randomized, controlled trial of an “embodied” virtual reality intervention for adults with low back pain

Christopher Eccleston\textsuperscript{a,b}, Emma Fisher\textsuperscript{a,b,c}, Sammel Liikkanen\textsuperscript{d}, Toni Sarapohja\textsuperscript{d}, Carina Stenfors\textsuperscript{d}, Satu K. Jääskeläinen\textsuperscript{e}, Andrew S.C. Rice\textsuperscript{f}, Leena Mattila\textsuperscript{d}, Taru Blom\textsuperscript{d}, J. Raymond Bratty\textsuperscript{d}

Abstract

Adults with chronic low back pain, disability, moderate-to-severe pain, and high fear of movement and reinjury were recruited into a trial of a novel, automated, digital therapeutics, virtual reality, psychological intervention for pain (DTxP). We conducted a 3-arm, prospective, double-blind, pilot, randomized, controlled trial comparing DTxP with a sham placebo comparator and an open-label standard care. Participants were enrolled for 6 to 8 weeks, after which, the standard care control arm were rerandomized to receive either the DTxP or sham placebo. Forty-two participants completed assessments at baseline, immediately posttreatment (6-8 weeks), 9-week, and 5-month follow-up. We found that participants in the DTxP group reported greater reductions in fear of movement and better global impression of change when compared with sham placebo and standard care post treatment. No other group differences were noted at posttreatment or follow-up. When compared with baseline, participants in the DTxP group reported lower disability at 5-month follow-up, lower pain interference and fear of movement post treatment and follow-up, and lower pain intensity at posttreatment. The sham placebo group also reported lower disability and fear of movement at 5-month follow-up compared with baseline. Standard care did not report any significant changes. There were a number of adverse events, with one participant reporting a serious adverse event in the sham placebo, which was not related to treatment. No substantial changes in medications were noted, and participants in the DTxP group reported positive gaming experiences.

Keywords: Chronic low back pain, Virtual reality, Randomized controlled trial, Feasibility study, Psychological treatment

1. Introduction

Fear of movement, characterized by the dominant belief that pain and reinjury are the likely consequence of movement, can maintain and exacerbate disability associated with chronic pain.\textsuperscript{5,11} The rigidity of beliefs of inevitable harm, distracting worry and self-defeating cognition, and subsequent social withdrawal, are all targets of intervention in evidence-supported cognitive behavioral therapy (CBT) and CBT-informed rehabilitation.\textsuperscript{20,42,60,67}

Access to CBT informed rehabilitation, however, is rare, in part due to a shortage of healthcare professionals with the appropriate skill and experience, and reliance on delivery methods requiring the physical co-location of patients and healthcare professionals. Internet and telemedicine solutions have gone some way to allow for remote treatment delivery.\textsuperscript{19,53} and telemedicine adoption has recently been accelerated by the public health measures introduced in response to the COVID-19 pandemic.\textsuperscript{15} Despite growth in experience with technologically mediated consultation, widespread adoption of digital therapeutics is still some way off.

Virtual reality (VR) technologies offer significant opportunities in psychotherapy generally\textsuperscript{39} and in pain management and rehabilitation specifically.\textsuperscript{34,63} Virtual reality can enable existing treatments to be offered at scale through automation, but it can also improve the content and impact of both assessment and treatments to be offered at scale through automation, but it can also improve the content and impact of both assessment and intervention. Although there are many reports of VR for analgesia\textsuperscript{30,49,56} and sedation,\textsuperscript{54} there are few examples of attempted use in chronic pain.\textsuperscript{34} Notable exceptions include randomized controlled trials of skills-based interventions with a focus on emotional self-regulation\textsuperscript{1,12,24,25} and rehabilitation interventions with a focus on education and increasing movement.\textsuperscript{23,61}

We designed, developed, and tested a VR intervention for use in adults with chronic pain who have high disability and high fear of movement and reinjury. The content was maximized to make use of the core properties of VR: immersion, exploration, and experimentation. The intervention requires daily goal-oriented movement that increases in both intensity and range of movement.
The content is guided by an “embodied” model of the psychology of pain in which disability and distress arise from (1) the privileged access to consciousness of threat-relevant interoception (ie, bodily sensations are more likely to be attended to, interpreted as threatening, and acted upon), (2) avoidance behavior maintained with reinforcement by immediate and general safety signals and generalized to multiple contexts, and (3) consequent social and cognitive failure supported by self-defeating behavior and cognition.13,14,59 Moving without concern for harm, experiencing positive outcomes after self-determined action, and safely experimenting with core beliefs can all be delivered in an immersive environment within VR. Furthermore, given the public health goal to scale access to evidence-based treatments, the intervention was protocolized and automated, so it could run without access to an interpreting healthcare professional.

We report a pilot, randomized, controlled trial comparing the active VR intervention with a sham placebo comparator and a standard care group. The primary aim of this study was to determine any comparative efficacy and report any adverse events. We also report on experience with the VR interventions.

2. Methods

2.1. Trial design

A pilot 3-arm prospective, double-blind, randomized, controlled trial comparing a digital therapeutics software solution for chronic pain known here as digital therapeutics for pain (DTxP), a sham placebo comparator, and an open standard care. Participants followed their allocated treatment for 6 to 8 weeks and were assessed immediately posttreatment and again 9 weeks after randomization to ensure a fixed assessment timepoint for all participants. After unblinding, participants continued in an open-label extended follow-up period for a further 3 months (end of study is 5 months post randomization). The treatment was protocolized, automated, and delivered by a machine mentor, which was blind to allocation. Furthermore, participants and some study staff were blind to allocation in the DTxP and sham placebo arms. Participants in the standard care arm were open to allocation but were rerandomized to receive the DTxP or sham placebo after the week-9 follow-up and then blinded to their new allocation (Fig. 1). The study was preregistered on clinicaltrials.gov (NCT04225884), and the trial design and statistical protocols are available in the supplementary material (available at http://links.lww.com/PAIN/B590). Specifically, the protocol outlines initial proof of concept with 30 participants and potential expansion arms for up to 100 participants, which could be based on learnings from this study had the device failed or for patients with different etiologies of pain. The expansion arms were not used after results of the feasibility study were reviewed. The Helsinki University Ethical Committee gave ethical approval for the study (approval number HUS/3111/2019).

2.2. Participants and setting

The inclusion criteria were (1) adults ≥18 years of age; (2) reported low back pain for at least 3 months, with average pain intensity of ≥4/10 over the past week on a 0 to 10 numeric rating scale, Oswestry Disability Index (ODI) of ≥26%, and medium (34-41) or high (42-68) Tampa Scale of Kinesiophobia (TSK) score; (3) provided written informed consent; (4) were Finnish speaking; (5) had a clear, flat ground surface at home of at least 2m² in which they could interact with a digital therapeutics intervention for pain; and (6) could bend without severe pain.

Several exclusion criteria were applied, including (1) a history of epilepsy, migraine, vertigo, or psychosis; (2) a confirmed diagnosis of cancer; (3) susceptibility to motion sickness requiring treatment; (4) pregnancy; (5) current psychotherapy that contra-indicated the goals of the DTxP; (6) severe or acute structural pathologies that the intervention could make worse, as assessed by a physician; (7) having had psychotherapy in the previous 2 years or currently receiving psychotherapy (so to avoid any interactions of the experimental conditions in this trial with previous therapies and to protect blinded allocation); (8) reported any condition that affected posture or balance; (9) any prior participation in a digital therapeutics intervention for pain study (eg, the feasibility testing study) or had participated in any part of the current study.

We recruited participants from January 2020 to October 2020 through internet advertisements (via www.orion.fl) and social media (via Facebook). Participants were screened using the above criteria and then randomized into the arms of the treatment.

2.3. Procedures

2.3.1. Randomization and blinding

Randomization was performed using a random numbers generator by an independent randomization expert who was not part of the study team. Participants were randomized to a group using a 1:1:1 allocation ratio and block size of 3, stratified by their TSK score (medium or high score). The randomization expert then sent the randomization list via email to the unblinded study members who allocated the participants into the trial condition following the randomization order. For the second randomization of the standard care group into the DTxP or sham placebo group after the 9-week assessment, a 1:1 allocation ratio and block size of 2 were used, stratified by medium or high score on the TSK. Further help and instructions were given by an unblinded study member, without a blinded study team member being present.

Participants were not informed of their treatment allocation, and treatments were only referred to by either “treatment A” or “treatment B” on study materials. Participants were not allowed to compare treatments. Two groups of personnel were formed: an unblinded study team and a blinded study team.

The unblinded study team’s responsibilities included the following:

(1) Not revealing treatment allocations
(2) Issuing the correct allocated device to the participant and supervising the training
(3) Technically supporting participants throughout the duration of the study
(4) Calling the participant to elicit adverse events, device deficiencies, or adverse device effect, recording this and then entering the information to the electronic shared database in such a way that the treatment allocation remained concealed.

The blinded study team group included the PI and staff conducting the analyses.

2.3.2. Study flow

Participants were screened and then gave consent to be involved in the study. Participants attended the testing unit during the first session. During this session, participants were given a VR wireless headset and hand controllers, corresponding to their randomization number. Participants were shown how to use the
headset, handheld controllers, and all movements required by the unblinded study team. The DTxP or sham program was preloaded. Early during recruitment, in-person sessions were suspended due to COVID-19 and replaced with training videos, instructions, and phone support. Virtual reality headsets were delivered to participants’ homes. During use in home, participants were instructed to use the VR technology on a clear, flat ground surface 2m x 2m in size to prevent injury. Participants range of movement and stability were assessed by staff at the first session. Participants completed assessments before treatment (baseline), posttreatment (6-8 weeks), at 9-week follow-up, and at the end of study (5 months postrandomization). Some outcomes were assessed more frequently as outlined in our protocol but not reported here. After 9-week follow-up assessment, participants in the standard care group were rerandomized into the DTxP or sham placebo comparator for 6 to 8 weeks and completed follow-up at 9 weeks and 5 months post randomization.

2.4. Treatment groups

2.4.1. Design model

We adopted a “design thinking” user-centric methodology to create both the DTxP and sham placebo intervention, which involves the iterative use of abduction to develop solution-focused designs. Multiple stakeholders were interviewed for their insights and input at the design, development, and implementation stages, including patients, pain practitioners, pain research experts, UX design experts, and designers. Multiple bespoke design tools were created, to track content fidelity, quality control, and safety (available on request). The DTxP and sham placebo intervention were principally designed by Professor Eccleston, who has a UK Health Professionals Council registration to practise health psychology (PYL03729), 15 years of experience in interdisciplinary residential chronic pain management, and has written on the methods of embodied psychology. The protocols and inclusion and exclusion criteria were reviewed by Professors Rice and Jääskeläinen, and the movements promoted in the activity were reviewed by experts from the Finnish Spinal Health Association.

2.4.2. Hardware and software

Both the DTxP and sham placebo were built and tested using Unity v2019.3.711 and delivered on an off-the-shelf OCULUS Quest and Touch VR headset and accompanying Touch handheld controllers given to participants for home use. All the scenes in VR run at a refresh rate minimum of 70 Hz.

2.4.3. Duration and exposure

Both the DTxP and sham placebo were designed to last 15 to 60 minutes per session. There were 5 sessions scheduled for each week, resulting in 30 unique days that were designed to be delivered over 6 to 8 weeks.

2.4.4. Virtual environments

Both treatments included an “inside space” rendered as a summer cabin and an “outside space” rendered as a lakeshore and copse with fruit trees. Ambient sound was present in the outside space commensurate with summer wildlife.

2.4.5. Digital therapeutics software solution for chronic pain

Participants completed a fully immersive VR experience based on a cognitive behavioral intervention maximized to make use of the core properties of VR: immersion, exploration, and experimentation. The intervention is guided by an “embodied” model of the psychology of pain aimed to reduce fear of movement and reinjury by creating a safe virtual environment to encourage exploration and repeated movement.

Participants always enter the virtual world via the inside space (Fig. 2). When in the cabin, they encounter a virtual (disembodied) mentor. The mentor communicated with a male voice with optional text script that appeared in view for participants to read. The mentor acted as a guide. He welcomed participants, helped them navigate the space, gave instructions on tasks, presented the psychological content inviting reflection, and set homework in the real (non-VR) world. The mentor invited the participant to the outside space where they engaged in a gamified “fruit-picking” activity (Fig. 3). The task involved picking or stacking geometrically shaped fruits. Fruits from trees appeared in all 4 quadrants of their peripersonal space. Their location and frequency increased through the experience. During the stacking task, the fruits needed to be stacked in a particular order, so the shapes could fit together. The activity was designed to promote fine and gross motor movements typically avoided by low back pain patients fearful of movement and reinjury.

The behavior change content was divided into 24 modules. In each 5-day period, new material was delivered on the first, third,
and fifth days. The intervening 2 days (second and fourth) were practice days in which no new material was delivered, but participants could revisit material. Day 5 always involved homework setting (except the final day), and day 1 always involved homework review (except the first day). Each 5-day period had a general theme: orientation, education and exploration, problem solving, setback planning, use of peripersonal space, or consolidation and generalization.

The behavior change content was delivered by the mentor in the inside space before going outside. The material was organized around 4 behavior change themes. First, content was aimed at building and maintaining a working alliance between mentor and participant. In particular, the mentor always presented a rationale, offered education, and adopted a relational stance with compassionate regard. Where possible, self-deprecating humor was employed. Specific material included education on the relationships between pain and tissue damage, goal and value determination, reflection on goal-value discrepancy, goal setting and pacing, and positive reinforcement for engagement and activity. Second, the intervention had a strong focus on embodied reactivity; participants were encouraged to move within their peripersonal space, owning and being agents within that space, and engaging in a full range of motion physical activities, repeatedly. The mentor explained the rationale for the activity in the outside space but also encouraged and rewarded engagement. Third, we promoted courageous engagement to counter feared movement and activity by providing education on avoidance behavior, promoting behavioral experiment in confronting feared activity, suggesting reflection on movement achieved despite beliefs of inability or fear of injury and pain, and providing reinforcement for engagement. Fourth, there was material promoting mastery, with insight into common cognitive and social difficulties, and techniques offered to promote problem solving, reflection on change, and increased self-efficacy for change.

More details of the content of the DTxP are available as appendices (available at http://links.lww.com/PAIN/B590), including Appendix A, http://links.lww.com/PAIN/B590 showing the experience flow over the 30 days, Appendix B, http://links.lww.com/PAIN/B590 showing the themes, module placement, module labels, and content, and Appendix C, http://links.lww.com/PAIN/B590 shows the 4 behavior change themes,
description of content, and how the modules map onto the themes. For comprehensiveness, we completed the TiDieR checklist on intervention description in Appendix D, http://links.lww.com/PAIN/B590.31

Three visual metaphors were used in the inside space to support interaction. First, a map of the virtual world served as a device for participants to teleport to the outside space (a book next to an umbrella in the shore area of the outside space allowed participants to teleport back inside). Second, after each module was completed, a module book appeared on a bookshelf that allowed participants to see progress and to re-run material if wanted. And third, a growing plant was used to show progress in the outside “fruit-picking” activity. The mentor guided participants to see changes in these objects and verbally rewarded progress.

2.4.6. Sham placebo comparator

Participants in the sham placebo comparator received the same VR headset as the participants in the DTxP arm. In line with the VR-Core trial guidelines, we selected the most stringent comparator possible, of 3-D “… immersive and active experiences within a headset.”45 The virtual environment showed a similar seashore environment to the DTxP arm. None of the content provided in the DTxP was presented. Instead, the participants viewed text that instructed them to relax and enjoy the environment as used in the DTxP.

2.4.7. Standard care

Participants in the standard care condition received no intervention, instructions, or education. During the treatment phase, participants continued with their standard care as usual for 6 to 8 weeks. Participants visited the study site for screening on day 1 and assessment at 6 to 8 weeks after randomization. For participants enrolled during the COVID pandemic, who therefore could not attend an in-person visit, procedures were undertaken by video call. At the end of the first treatment phase, participants were rescreened for inclusion and completed questionnaires, before being rerandomized to either the DTxP or sham placebo comparator.

2.4.8. Translation

All material was written in English and then translated into Finnish, and then independently back translated into English to check for meaning. Any corrections were introduced to the final Finnish version.

2.5. Measures

All measures were delivered in Finnish. The primary end point was posttreatment (6-8 weeks). Disability, fear of movement, numerical rating scale (NRS) for pain intensity, and patient clinical global impression of change measures were assessed posttreatment, at 9 weeks, and at the end of the study (5-month follow-up). To reduce burden on participants, other measures were only assessed at posttreatment and 9-week follow-up.

2.5.1. Disability

Participants completed the Oswestry Disability Index (ODI version 2.2,46 a self-report measure assessing physical disability in participants with chronic pain. The ODI includes 10 sections; participants chose one statement from each section, which was rated from 0 to 5 and then summed. Scores ranged from 0 to 50. We dichotomized responses; participants reporting ≤22 were categorized as responders and participants reporting >23 as nonresponders.64

2.5.2. Pain interference

Participants completed the Patient-Reported Outcomes Information System (PROMIS) 6-item Pain Interference Score (6b,1 which ranges from 6 to 30 points with higher scores indicating higher levels of pain interference. Participants responded to items on a scale from 1 to 5 (1 = not at all, 5 = very much). This measure was assessed at baseline and posttreatment. The raw score from the questionnaire was then translated into a t-score to provide a standardized score with a mean of 50 (SD = 10). The conversion to a t-score was a post hoc decision but is the best practice with this measure.1

2.5.3. Fear of movement and reinjury

Participants completed the Tampa Scale of Kinesiophobia17,35,41 which includes 17 items assessing beliefs about pain-related movement and possible further pain and reinjury using a 4-point Likert scale from strongly agree to strongly disagree. Higher scores indicate higher fear of movement and reinjury.

2.5.4. Pain intensity

Participants completed a Numerical Rating Scale48 at baseline, posttreatment, and at the end of the study to assess the average pain, maximum pain, and minimum pain over the last week. Participants responded on a 0 to 10 scale (0 = no pain at all; 10 = worse pain imaginable). Participants also completed the PROMIS pain intensity 3a measure to assess current, average, and worst pain7 at baseline and posttreatment. Similar to the PROMIS 6b assessment, scores were translated to a t-score to provide a standardized mean of 50 (SD = 10). The conversion to a t-score was not identified in the protocol but is the best practice with this measure.

2.5.5. Pain medications

Participants were asked to report any increases in their pain medication during the study.

2.5.6. Quality of life

Participants completed the European Quality of Life 5-dimension, 5-level scale (EuroQoL-5D-5L).29,33 Five dimensions are assessed, including mobility, self-care, usual activities, pain/discomfort, and anxiety and depression. Each item is scored from 1 to 5 (1 = no problems; 5 = unable to/extreme problems). Participants also reported their overall health condition using a visual analogue scale from 0 to 100 (0 = the worst health you can imagine and 100 = the best health you can imagine). There are no country-specific index values published for Finnish populations.

2.5.7. Adverse events

We collected treatment-related adverse events, serious treatment-related adverse events, adverse device effects, and serious adverse device effects.
(1) Adverse events were defined as any untoward medical occurrence, unintended disease or injury, or any untoward clinical signs, whether or not related to the investigational medical device. Adverse events were categorized as mild (discomfort noticed but does not affect normal activity), moderate (discomfort sufficient to reduce or affect normal daily activity), or severe (incapacitating with inability to work or perform normal daily activities).

(2) Serious adverse events (SAE) were defined as any event leading to death or serious deterioration in health of the participant, or fetal distress, death, or congenital abnormality or birth defect.

(3) Adverse device effects were defined as any adverse effect related to the use of an investigational medical device.

(4) Serious adverse device effects were defined as any effect that has resulted in any of the consequences characteristic of an SAE.

### 2.5.8. Patient clinical global Impression of change

Participants were asked to report their global impression of change on a scale from 1 to 7 (1 = very much improved, 7 = very much worse).

### 2.5.9. Feedback on the software

The Game Experience Questionnaire\(^2\),\(^6\) was completed by participants after the first VR exposure and at the end of intervention. Participants completed the original 14 items, together with the modified measure, which is specific to low back pain. These questionnaires have previously been used to evaluate VR treatments in healthcare settings.\(^3\),\(^8\)

### 2.6. Data analysis

Statistical analyses were conducted in SAS (version 9.4) software. The primary end point was post-treatment, 6 to 8 weeks after randomization. The power calculation for the study considered the standard deviation for the TSK, which is 8 for participants with lower back pain.\(^5\)\(^2\) Thus, with \( n = 10 \), the precision reached in terms of 95% confidence interval is approximately \( \pm 5 \) units for each group’s mean values. This was considered sufficient precision for gaining preliminary information of any effects on kinesiophobia.

We conducted intention-to-treat (ITT) analyses. All randomized participants with completed baseline questionnaires were entered into ITT analyses. We used a mixed model for repeated measures, which can provide unbiased estimates from incomplete data using subject level random effects. When analyzing data, we found 15% missing at 6 to 8 weeks across outcomes.

We used descriptive statistics to summarize demographics of the sample. Where categorical data are available, we report frequency statistics and where continuous data were collected, we report means and standard deviations. We did not specify a primary hypothesis for the study. Descriptive data are reported for all questionnaires.

As outlined earlier, at the end of the first treatment phase, participants in the standard care group for the first treatment phase were rerandomized to either the DTxP or sham placebo group. We analyzed all participants who had completed DTxP arm, regardless of time of entry into the arm. This means that participants who entered the treatment arms after a period of standard care are combined with participants who had received the treatment in the first phase. Participants who had participated in the standard care intervention first were asked to complete new baseline measures before starting DTxP or sham placebo control treatment in the second phase, and we used those in our analyses.

The TSK and pain intensity NRS outcomes were analyzed using a mixed model for repeated measures to assess change from baseline. Models included fixed effects for planned treatment, randomization strata, study visit and a visit by treatment interaction, random effects for the participant, and baseline scores for each outcome were included as a covariate. Efficacy was evaluated based on the fitted model, using contrasts to obtain an estimate of difference between treatments.

The ODI and PROMIS measures outcomes were analyzed using an analysis of covariance (ANCOVA). The models included fixed effects for planned treatment and randomization strata; random effects for the participant; and the baseline scores as a covariate. Patient clinical global impression of change was analyzed using an ANOVA including fixed effects for planned treatment and randomization strata and random effects for the participant. A post hoc Cochran–Mantel–Haenszel analyzing PGIC is reported in Appendix E (available at http://links.lww.com/PAIN/B590). Changes to the number of medications are described. No between-group analysis was planned for quality of life, and therefore, we only describe this outcome. Changes from baseline to posttreatment are reported for all outcomes. We also analyzed responder analyses for the TSK and ODI measures and compared groups using either chi-squared or Fisher exact test.

We planned several subgroup analyses based on an expansion protocol that allowed for up to 100 participants to be recruited into the study. Subgroup analyses were only planned for the TSK outcome, based on age (<55 years vs ≥55 years of age), sex, TSK scores (<42 vs ≥42), NRS pain intensity (<6 vs ≥6), ODI (35 vs ≥35), Keele StarT Back (high, medium, low), and CLBP ongoing (<1, 1 vs 5, >5) and are reported in Appendix F (available at http://links.lww.com/PAIN/B590). Additional participants were not recruited, so subgroup analyses should be interpreted cautiously.

### 3. Results

#### 3.1. Participants

We assessed 72 participants for eligibility. Thirty-four met the inclusion criteria, and we randomized 11 participants to the DTxP, 12 to placebo sham, and 11 to standard care (Fig. 4). In the second randomization and allocation, 8 participants who were allocated to standard care were rerandomized to either the DTxP or the sham placebo group. For the blinded comparison between DTxP and the sham placebo, there are 42 participants included in the ITT analyses; 5 were male and 37 were female (mean age, 54.69 years; SD, 10.20). All participants were white, and one participant identified as Hispanic or Latino. Participants reported an average pain intensity (NRS) of 5.56 (SD 1.75) at baseline. Two participants had low back pain between 6 and 12 months, 7 reported back pain between 1 and 5 years, and 33 participants reported back pain lasting for longer than 5 years. Table 1 shows participant demographics.

#### 3.2. Outcome variables

Table 2 shows means and standard deviations of measures at the relevant time points, and between-group differences are reported in Table 3. Nine-week follow-up data are reported in Appendix G (available at http://links.lww.com/PAIN/B590).
3.2.1. Disability

A repeated-measures ANCOVA did not show an interaction between treatment and visit (P = 0.42), and no simple main effects differences were found between groups at any time point for ODI scores.

Participants in the DTxP group reported lower ODI scores post treatment (P = 0.05) and at the end of the study (P = 0.04) compared with baseline. Participants in the sham placebo comparator did not reduce their ODI scores at posttreatment (P = 0.53) but did report lower ODI scores at the end of the study compared with baseline (P < 0.01). Standard care did not result in lower ODI scores compared with baseline at posttreatment (P = 0.66).

A post hoc analysis of responders to treatment using the ODI cutoffs (responders categorized a priori as reporting ≥52%) found that 6 of 12 participants in the DTxP arm, 1 of 13 in the sham placebo comparator, and 1 of 10 in the standard care group were categorized as responders on the ODI at posttreatment (difference between groups analyzed with chi-square test P = 0.04). At follow-up, 5 of 11 participants in the DTxP arm and 2 of 12 participants in the placebo control were categorized as responders on the ODI (difference between groups analyzed with Fisher exact test P = 0.07). Because of the inclusion criteria, no participants scored <26% at baseline.

3.2.2. Pain interference

When participants in the DTxP group were compared with the sham placebo comparator post treatment, participants receiving DTxP reported lower pain interference (P = 0.05). No differences were found between DTxP and standard care, or the sham placebo comparator group and standard care posttreatment.

Participants in the DTxP group reported lower pain interference (PROMIS 6b) posttreatment compared with baseline (P < 0.01). Participants in the sham placebo comparator (P = 0.39) and standard care intervention (P = 0.22) did not report lower scores compared with baseline. This outcome was not assessed at 5-months follow-up.

3.2.3. Fear of movement or reinjury

A repeated-measures ANCOVA did not reveal an interaction of treatment by visit (P = 0.05). However, simple effects were revealed. When compared with the sham placebo and standard care groups post treatment, participants in the DTxP arm reported lower TSK scores. There was no difference between the sham placebo comparator and standard care posttreatment.

When comparing DTxP and the sham placebo comparator at 5-month follow-up, there were no differences between the groups (Table 3 and Fig. 5).

Participants in the DTxP group reported lower TSK scores at postintervention (6-8 weeks; P < 0.001) and 5-month follow-up (P < 0.01) compared with baseline. The sham placebo control did not reduce TSK scores at posttreatment (P = 0.29) but did at follow-up (P = 0.02) when compared with baseline. The standard care did not reduce TSK scores at postintervention (P = 0.84).

In post hoc analysis, we determined responders to treatment as those participants who reduced their TSK scores by 4 points, which may be considered a clinically relevant change. We found that 10 of 12 participants (83%) in the DTxP arm, 5 of 13 (38%) in the sham placebo comparator, and 2 of 10 (20%) in the standard care group were responders post treatment (difference between groups analysed with \( \chi^2 \) test \( P = <0.01 \)). At 5-month follow-up, 8 of 11 (73%) in the DTxP arm and 7 of 12 (58%) in the sham placebo comparator arm were categorized as responders (difference between groups analysed with Fisher exact test \( P = 0.88 \)).

3.2.4. Numerical rating scale pain intensity

We did not find an interaction effect for treatment vs visit (P = 0.84). When comparing groups, we found no simple main effects for differences between groups at any time point for average pain intensity.

Participants in the DTxP group reported lower average pain intensity post treatment compared with baseline (P = 0.02) but not at the end of the study (P = 0.06). Participants in the sham placebo comparator and standard care arms did not report lower average pain intensity post treatment (P = 0.18; P = 0.12, respectively), but the sham placebo comparator resulted in lower average pain intensity at 5-month follow-up compared with baseline (P = 0.02).

For maximum and minimum pain, there were no interaction effects (P = 0.90; P = 0.85, respectively). Similarly, there were no simple main effects for any between-group comparisons at any time point when compared with baseline scores for minimum or maximum pain scores.

3.2.5. Patient-reported outcomes information system 3a pain intensity

There were no between-group differences between the 3 groups post treatment. Participants in the DTxP group reported lower
**Figure 4. CONSORT Flow diagram.**
## Table 2
Outcome measures (intention-to-treat [ITT] sample).

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>DTxP (n = 14; mean (SD))</th>
<th>Sham placebo (n = 17; mean (SD))</th>
<th>Standard care (n = 11; mean (SD))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oswestry Disability Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>36.0 (7.6)</td>
<td>37.2 (9.4)</td>
<td>36.2 (7.6)</td>
</tr>
<tr>
<td>Day 1</td>
<td>34.8 (11.0)</td>
<td>38.2 (9.4)</td>
<td>33.8 (7.5)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>28.8 (15.6)*</td>
<td>38.5 (16.2)</td>
<td>32.8 (8.6)</td>
</tr>
<tr>
<td>End of the study</td>
<td>29.1 (17.2)*</td>
<td>31.3 (12.8)**</td>
<td>—</td>
</tr>
<tr>
<td>Pain interference (PROMIS 6b)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>64.5 (3.7)</td>
<td>63.1 (3.4)</td>
<td>63.1 (2.5)</td>
</tr>
<tr>
<td>Day 1</td>
<td>63.6 (2.3)</td>
<td>63.2 (2.9)</td>
<td>62.1 (3.5)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>59.0 (6.6)**</td>
<td>62.6 (5.3)</td>
<td>60.9 (3.8)</td>
</tr>
<tr>
<td>Tampa Scale for Kinesiophobia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>41.9 (4.4)</td>
<td>43.2 (6.0)</td>
<td>42.5 (5.4)</td>
</tr>
<tr>
<td>Day 1</td>
<td>39.5 (4.4)</td>
<td>44.3 (5.9)</td>
<td>40.3 (4.6)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>33.7 (7.4)**</td>
<td>43.1 (8.5)</td>
<td>39.8 (7.1)</td>
</tr>
<tr>
<td>End of the study</td>
<td>33.7 (9.2)**</td>
<td>40.2 (7.5)*</td>
<td>—</td>
</tr>
<tr>
<td>Average pain (NRS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>6.0 (1.4)</td>
<td>6.1 (1.4)</td>
<td>5.7 (1.6)</td>
</tr>
<tr>
<td>Day 1</td>
<td>5.7 (1.4)</td>
<td>5.6 (1.9)</td>
<td>5.4 (2.0)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>4.1 (1.7)*</td>
<td>4.8 (2.3)</td>
<td>4.4 (2.4)</td>
</tr>
<tr>
<td>End of the study</td>
<td>4.4 (1.9)</td>
<td>4.0 (1.8)*</td>
<td>—</td>
</tr>
<tr>
<td>Maximum pain (NRS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>8.2 (0.9)</td>
<td>8.3 (0.9)</td>
<td>8.5 (0.9)</td>
</tr>
<tr>
<td>Day 1</td>
<td>7.5 (1.3)</td>
<td>7.5 (1.8)</td>
<td>7.4 (1.6)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>6.0 (2.4)</td>
<td>6.9 (2.5)</td>
<td>6.9 (2.5)</td>
</tr>
<tr>
<td>End of the study</td>
<td>6.8 (2.1)</td>
<td>6.3 (2.7)*</td>
<td>—</td>
</tr>
<tr>
<td>Minimum pain (NRS)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>3.5 (2.1)</td>
<td>4.2 (2.0)</td>
<td>4.5 (1.9)</td>
</tr>
<tr>
<td>Day 1</td>
<td>3.8 (1.7)</td>
<td>4.4 (2.0)</td>
<td>3.6 (2.7)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>2.6 (1.6)</td>
<td>3.5 (2.3)</td>
<td>2.8 (2.5)</td>
</tr>
<tr>
<td>End of the study</td>
<td>2.7 (1.7)</td>
<td>2.6 (1.7)*</td>
<td>—</td>
</tr>
<tr>
<td>Pain intensity (PROMIS 3a)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>66.5 (4.1)</td>
<td>65.1 (5.4)</td>
<td>63.0 (5.5)</td>
</tr>
<tr>
<td>Day 1</td>
<td>66.1 (5.6)</td>
<td>64.5 (5.2)</td>
<td>64.5 (5.9)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>60.0 (7.5)**</td>
<td>61.9 (8.3)</td>
<td>61.0 (5.9)</td>
</tr>
<tr>
<td>EQ-5D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobility</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>2.2 (0.7)</td>
<td>2.5 (0.9)</td>
<td>2.1 (0.5)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>2.0 (1.0)</td>
<td>2.3 (0.9)</td>
<td>2.1 (0.6)</td>
</tr>
<tr>
<td>Usual activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>2.6 (0.8)</td>
<td>2.2 (0.6)</td>
<td>1.9 (0.5)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>2.2 (1.2)</td>
<td>2.2 (0.9)</td>
<td>1.8 (0.6)</td>
</tr>
<tr>
<td>Anxiety/depression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>1.7 (0.9)</td>
<td>1.6 (0.7)</td>
<td>1.2 (0.4)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>2.0 (1.2)</td>
<td>1.8 (0.8)</td>
<td>1.2 (0.4)</td>
</tr>
<tr>
<td>Pain/discomfort</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>3.2 (0.4)</td>
<td>2.7 (0.7)</td>
<td>2.8 (0.8)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>2.5 (0.8)</td>
<td>2.6 (0.8)</td>
<td>2.6 (0.7)</td>
</tr>
<tr>
<td>Self-care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>1.5 (0.8)</td>
<td>1.6 (0.6)</td>
<td>1.8 (0.6)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>1.3 (0.7)</td>
<td>1.7 (0.6)</td>
<td>1.5 (0.7)</td>
</tr>
<tr>
<td>Health state (0-100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>47.7 (16.8)</td>
<td>63.8 (15.1)</td>
<td>55.7 (19.6)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>66.1 (22.2)</td>
<td>58.1 (26.8)</td>
<td>62.0 (23.9)</td>
</tr>
<tr>
<td>PGIC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Posttreatment</td>
<td>2.7 (1.4)**</td>
<td>3.8 (1.5)**</td>
<td>3.9 (0.7)**</td>
</tr>
<tr>
<td>End of the study</td>
<td>3.0 (1.5)**</td>
<td>3.0 (1.5)**</td>
<td>—</td>
</tr>
</tbody>
</table>

Significance levels are compared with day 1, *p < 0.05, **p < 0.01, ***p < 0.001.
M, mean; NRS, numerical rating scale; PGIC, patient global impression of change; PROMIS, Patient-Reported outcomes Information System.
pain intensity at posttreatment compared with baseline \( (P < 0.01) \), whereas participants in the sham placebo comparator \( (P = 0.06) \) and standard care groups \( (P = 0.07) \) did not. This measure was not assessed at 5-month follow-up.

### 3.2.6. Changes in medication

Similar numbers of participants across the 3 groups were taking medications across the different classes of medications at baseline. Across all groups, 62% of participants were receiving nonsteroidal anti-inflammatory drugs, 50% were receiving opioids, 64% were taking paracetamol, 40% gabapentin or pregabalin, and 17% antidepressants. Additional treatments were taken as required, and no differences were identified between the groups.

### 3.2.7. Quality of life

Quality of life posttreatment scores were not analyzed between groups as determined in our protocol. No significant changes...
were noted for any group from baseline to posttreatment. The DTxP group scored lowest on the mobility (lower scores indicate better quality of life for that domain), pain/discomfort, and self-care domain, whereas the standard care group reported lowest scores on usual activities and anxiety/depression posttreatment. Results were comparable across the 3 groups on the 5 domains. The DTxP group reported the highest health state across all 3 groups post treatment (higher = better health on this domain).

### 3.2.8. Adverse events

Thirty-three participants reported 140 adverse events during the treatment period. Eleven participants reported 58 AEs considered relevant to treatment; participants in the sham placebo comparator reported the most treatment-related AEs, followed by the DTxP group, and then the standard care group (Table 4). A small number of participants reported AEs classed as severe (but not SAE) in each group (DTxP 6 participants reported 8 events; sham placebo comparator 5 participants reported 7 events; standard care 4 participants reported 7 events). These included musculoskeletal and connective tissue disorders (eg, arthralgia, back pain, and pain in extremity), nervous system disorders (eg, headache), and motion sickness. There were no SAE during the treatment phase.

During follow-up, there was 1 SAE (back pain) that occurred in the sham placebo group. This was considered unrelated to treatment and the participant recovered. At follow-up, 19 participants reported 44 AEs; 9 participants reported 12 mild AEs, 11 participants reported 18 moderate AEs, and 10 participants reported 14 severe AEs (Table 4).

Seven participants reported 20 device deficiencies in the DTxP group, and 6 participants reported 8 device deficiency events in the sham placebo comparator group. These included problems such as a connection problem, bright flashes when using the software, and the program stopping unexpectedly. One participant reported hardware issues of stripes on the eyeglasses in the sham placebo comparator group, and 2 participants in the DTxP group reported either that the hand controllers did not work or there was no voice when the program played.

#### Table 4

<table>
<thead>
<tr>
<th>Safety population</th>
<th>Adverse event type</th>
<th>DTxP (n=12)</th>
<th>Sham placebo (n=17)</th>
<th>Standard care (n=11)</th>
<th>Total (N=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Participant N, (%)</td>
<td>Event N</td>
<td>Participant N, (%)</td>
<td>Event N</td>
<td>Participant N, (%)</td>
</tr>
<tr>
<td>Posttreatment</td>
<td>All AEs</td>
<td>12 (100) 50</td>
<td>14 (82.4) 60</td>
<td>7 (63.6) 30</td>
<td>33 (82.5) 140</td>
</tr>
<tr>
<td></td>
<td>Mild AEs</td>
<td>4 (33.3) 17</td>
<td>6 (35.3) 17</td>
<td>2 (18.2) 7</td>
<td>12 (30.0) 41</td>
</tr>
<tr>
<td></td>
<td>Moderate AEs</td>
<td>10 (83.3) 25</td>
<td>11 (64.7) 36</td>
<td>6 (54.5) 16</td>
<td>27 (67.5) 77</td>
</tr>
<tr>
<td></td>
<td>Severe AEs</td>
<td>6 (50.0) 8</td>
<td>5 (29.4) 7</td>
<td>4 (36.4) 7</td>
<td>15 (37.5) 22</td>
</tr>
<tr>
<td></td>
<td>Treatment-related AEs</td>
<td>3 (25.0) 25</td>
<td>6 (35.3) 29</td>
<td>2 (18.2) 4</td>
<td>11 (27.5) 58</td>
</tr>
<tr>
<td></td>
<td>Serious AEs</td>
<td>0 (0) 0</td>
<td>0 (0) 0</td>
<td>0 (0) 0</td>
<td>0 (0) 0</td>
</tr>
</tbody>
</table>

Follow-up

| All AEs           | 7 (58.3) 18 | 9 (52.9) 23 | 3 (27.3) 3 | 19 (47.5) 44 |
| Mild AEs          | 3 (25.0) 5  | 5 (29.4) 6  | 1 (9.1) 1  | 9 (22.5) 12  |
| Moderate AEs      | 5 (41.7) 6  | 5 (29.4) 11 | 1 (9.1) 1  | 11 (27.5) 18 |
| Severe AEs        | 4 (33.3) 7  | 5 (29.4) 6  | 1 (9.1) 1  | 10 (25.0) 14 |
| Serious AEs       | 1 (8.3) 1   | 1 (5.9) 1   | 1 (2.5) 1  | 1 (2.5) 1   |

DTxP, digital treatment for pain; AEs, adverse events.
3.2.9. Patient global impression of change

Participants in the DTxP group reported improved PGIC compared with the sham placebo comparator ($P = 0.04$) and standard care posttreatment ($P = 0.04$) but not compared with the sham placebo comparator group at the end of the study ($P = 0.98$). The sham placebo control and standard care groups did not differ posttreatment ($P = 0.81$).

3.2.10. Game experience questionnaire and modified game experience questionnaire

Participants in the DTxP group rated the VR treatment more positively compared with the sham placebo comparator group posttreatment (Figs. 6 and 7). Participants in the sham placebo comparator group endorsed negative items (eg, I felt bored, I felt frustrated) more compared with the DTxP group.

4. Discussion

Digital therapeutics for pain was superior to both a sham placebo comparator and standard care control in reducing fear of movement and reinjury and improving the global impression of change post treatment. There were no between-group differences post treatment or at follow-up for the remaining outcomes. The within-subject results from this double-blind, randomized, controlled trial show that for adults with moderate-to-severe chronic pain, who are highly disabled and have a high fear of movement and reinjury, that a VR psychological intervention (DTxP) reduced fear of movement, self-reported disability, pain intensity, and pain interference from baseline measures. Participants were generally positive about the VR experience, and no exceptional treatment-related adverse events were reported. These results add to the emerging RCT evidence base for the potential utility of VR as a tool to deliver psychological interventions in a physical rehabilitation context.\(^4,12,23-25,61\) This is the first such demonstration of a fully automated system.

Interpretation of these findings should be made within context. First, this is a clinically relevant population with long-standing chronic pain (75% with pain lasting longer than 5 years), who were disabled, had a high fear of movement, and had an average pain intensity of 5.56 out of 10 (SD 1.75) at baseline. Change in such a chronic population is rare. Second, this is a placebo-controlled trial of a psychological intervention with a sham intervention comparator. Controls over blinding were extensive, and significant effort was made to ensure that patients remained blind to allocation, and study investigators were blind throughout. Finally, with so few studies available in the field, we designed the study as a pilot by including multiple measures of interest. However, the active content of the experimental treatment (DTxP) was designed to simultaneously alter beliefs about movement and increase movement—exposing participants to disconfirmatory evidence of repeated goal-relevant movement without pain or injury. Compared with no treatment or sham treatment, this manipulation was successful. The study also provides a wealth of interesting data (see appendices, available at http://links.lww.com/PAIN/B590) to support further development and testing, including information on treatment content, subgroup analyses, and changes in judgements of global impression of change.

Taking these features into account, this study demonstrates the potential benefit and safety of VR delivered interventions, adding further empirical support to much theorized possible uses in chronic pain functional rehabilitation. There is a mature field of VR-based interventions for distraction in procedural pain,\(^34\) but chronic pain studies are at an early stage of development. In November 2021, the first Food and Drug Administration approval was given for EaseVRx,\(^21,22\) recognizing its effects in reducing pain, and in doing so, the Food and Drug Administration also created a new regulatory device classification,\(^18\) which may significantly reduce barriers to regulatory approval of VR interventions.

To develop the empirical base of VR based interventions in chronic pain and to increase their potential efficacy in reducing pain, disability, and distress, further research is needed in 4 main areas: (1) optimizing behavioral instruction for use in VR, (2) optimizing exposure and graded activity content for use in VR rehabilitation, (3) further automation, and (4) innovation in empirical evaluation.
First, early discussion of the use of technology to deliver behavior change instruction was largely focused on the correspondence between machine delivered and human delivered, holding human delivered intervention as a gold standard. Arguably, current developments in now pervasive high-powered portable computing and remote Internet access provide tools that can fundamentally change treatments. The emerging field of digital therapeutics encourages a focus on the novel aspects of communication and sensing technologies, in which computing and behavioral content are merged rather than one being the carrier for the other. In VR, this means that primary experimental research is critically needed into the behavior change properties, or the mechanism of action, of VR in altering experience. There are excellent examples already on immersion, illusion, and affect regulation but more are needed. In particular, the extent to which one can provide guided exploration through the use of a coach or mentor is unknown. The existing studies are focused in different clinical areas with different content, so direct comparison is difficult. Needed will be guidance on how to develop content, on necessary vs desirable content, and on a usable taxonomy of content to facilitate precision and comparison. The framework provided by Trost et al provides a helpful starting point.

Second, interventions that promote movement through exposure need further experimental investigation. Unknown is the optimal grading, order, type, intensity, and presentation of movement tasks applicable in VR. Although people with chronic pain report that after education, they valued learning that “pain does not mean my body is damaged” by definition, fear maintains avoidance and voluntary exposure to feared movement is rare. There is some guidance, however, not least in trials of therapist delivered exposure and graded activity in chronic pain, that can help. Similarly, there is discussion, guidance, and other investigators exploring possible uses in uncontrolled studies or in protocol. Further questions relate to the extent of gamification needed to ensure compliance with repetitive tasks. Speculatively, the role of attentional engagement may also be important in chronic as well as acute pain environments, to the extent that momentary engagement in goal-oriented tasks may provide temporary relief from pain and facilitate cognitive enrichment.

Third, an important feature of the solution explored here was its automaticity. Removing an interpreting therapist is not a new idea. There are many self-help manuals, audio and video recordings, “apps,” and telephone-based systems available for chronic pain patients. There are also research attempts in cognate fields to more directly mirror successful therapeutic behavior in a nonhuman agent, both disembodied, and embodied; see for example, social robots in which a physical agent operates in the real world providing advice, education, or comfort. To create an embodied nonhuman agent who can guide behavior change needs empirical guidance. The verbal dynamics of content has always been important, but in this environment, controlling the nonverbal will be as important, including vocal dynamics (order, tone, pause, affect), facial expression, and posture. Furthermore, in VR, the design of both the visual environment and the soundscape to support behavior change content become crucial. Interesting for future studies will be to extend our methods to include a measure of engagement with automatic agents, exploring their credibility, believability, and participant willingness to be guided automatically.

Finally, further study will need to address core challenges in VR research. Virtual reality is a complex intervention, and research designs will need to reflect the multiple stakeholders in the process and the inherent variability in practice and content. Relatedly, because computing develops faster than the traditional research cycle much of what is reported in the medical and scientific press, including this report, will likely discuss technology that will have been superseded, at the time this is being read. Needed is a forum for fast reporting and updating; a just-in-time collaborative-linked laboratory model. This is developing in paediatric pain and VR. Complexity and technological transience do not remove the need for high-quality and unbiased evaluation—arguably they amplify that need—but the randomized controlled trial alone is a poor fit for establishing efficacy and safety in digital therapeutics. Helpful would be the addition of idiographic research using single case experiment, linguistic analysis, and bioengineering, and further nomothetic research using large-scale real-time monitoring of mass use to allow for machine learning to establish which content supports behavior change and how safety is maintained.

Interpretation of these findings are of course limited by our design features: designed as a pilot the sample is small meaning...
that type II errors are likely[23]; although we powered this study on changes in fear of movement and reinjury, as a pilot, we deliberately did not identify a primary outcome, interested in the direction of multiple end points; also, we have data only to the end of the study. We did not formally assess patient beliefs about allocation, which could be investigated in future studies. Furthermore, we only asked participants to report increases in medication use and so have no data on treatment behavior outside of the interventions. Because of the Covid-19 pandemic, unplanned changes in protocol delivery were required, although randomization and allocation blinding were maintained throughout.

In conclusion, the results of this clinical trial add to the emerging field of VR interventions for chronic pain management and rehabilitation. Replication is necessary. Future invention could usefully develop personalized, embodied nonhuman agents to guide behavior change, make more use of the immersive properties of the environment, and further automate that content to allow for scalable use. Innovation is also needed in research methods for evaluating the efficacy and safety of complex digital therapeutics.

Conflict of interest statement
The authors have no conflicts of interest to declare.

Acknowledgments
The authors especially thank the patients who participated in this study. The authors also thank Maria Skog for project management, Minna Nissilä, and Alia Holopainen for their help with the protocol or managing the clinical team and the Orion Digital Medicine and Clinical development and Data Science teams for clinical and technical support. The Espoo team were involved in implementing the DtxP and Sham interventions. The Interventions were built by MakeHelsinki Ltd who are now part of Healthcare International.

Sammeli Liikkanen, Carina Stenfors, Toni Sarapohja, Taru Blom, and Leena Mattila are employees of Orion Corporation Orion Pharma, Finland; J. Raymond Bratty is a former employee of Orion Pharma. Christopher Eccleston, Andrew Rice (Imperial College London), and Professor Satu Jääskeläinen (University of Turku) acted as consultants of Orion Pharma, Finland. This project was funded by Orion Corporation and has also received support from Business Finland, the Finnish government organization for innovation funding and trade, travel, and investment promotion.

Appendix A. Supplemental digital content
Supplemental digital content associated with this article can be found online at http://links.lww.com/PAIN/B590.

Article history:
Received 22 November 2021
Received in revised form 28 January 2022
Accepted 13 February 2022
Available online 25 March 2022

References

